if you look at the drivers of big Pharma acquisitions they’re usually based on the target having a compelling pipeline (eg suite of antibody drug conjugates in oncology) or a standout groundbreaking drug like the Crown Jewels
——Dmx fits neither of those.
——/Beyond this trial the larder looks bare, and the dimx drug itself performing better than a placebo when other drugs in this space outperform it, well I can’t see Big Pharma boardrooms getting excited.
if you look at the drivers of big Pharma acquisitions they’re...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.015(4.17%) |
Mkt cap ! $192.4M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 37.0¢ | 34.5¢ | $832.2K | 2.345M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 36291 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 28985 | 1 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |